Compare GSK plc (GSK) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs VICI Properties Inc — how do they compare? GSK plc trades at $52.34 (market cap $101.34B), while VICI Properties Inc trades at $26.86 (market cap $28.97B). The key difference: GSK plc is far larger — about 3.5× VICI Properties Inc's market cap, and VICI Properties Inc pays the higher dividend (6.84%). Which is the better fit depends on your goals.
| GSK | VICI | |
|---|---|---|
Market Cap | $101.34B | $28.97B |
Sector | Health | Real Estate |
52-Week High | $61.18 | $33.93 |
52-Week Low | $36.20 | $25.94 |
Enterprise Value | $121.95B | $46.19B |
Dividend Yield | 3.49% | 6.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
VICI Properties trades at $26.72, up 1.67% with a bearish technical signal despite strong fundamentals including a 76.83% net margin and 11.33% ROE. Recent earnings show mixed results with Q1 2026 beating expectations while Q4 2025 missed. The company maintains robust cash flow with $2.51B from operations in 2025 and recently completed a Canadian portfolio acquisition, supporting its 6.62% dividend yield.
The stock presents value with a P/E of 9.01 below sector averages, but faces headwinds from tenant concentration risks and technical weakness. Analyst consensus remains strongly bullish with a $30 price target, suggesting 12% upside potential if operational stability persists amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
